![Breaking News: Ventyx Biosciences Begins Phase 1 Trial for VTX3232, a Revolutionary CNS-Penetrant NLRP3 Inhibitor](https://marketsgonewild.com/wp-content/uploads/2025/01/Breaking-News-Ventyx-Biosciences-Begins-Phase-1-Trial-for-VTX3232-a-Revolutionary-CNS-Penetrant-NLRP3-Inhibitor.gif)
Breaking News: Ventyx Biosciences Begins Phase 1 Trial for VTX3232, a Revolutionary CNS-Penetrant NLRP3 Inhibitor
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232 Topline Data Expected in H1 2024 ENCINITAS, Calif., June 14, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) Ventyx Biosciences, a clinical-stage biopharmaceutical company, has recently announced the initiation of dosing in a Phase 1 trial of VTX3232. This novel oral…